Literature DB >> 33998886

Synthetic Cannabinoid-Related Deaths in England, 2012-2019.

Pruntha Yoganathan1, Hugh Claridge1, Lucy Chester2, Amir Englund3,4, Nicola J Kalk3,4,5, Caroline S Copeland1,6.   

Abstract

Aim: To identify drug-related death trends associated with synthetic cannabinoid receptor agonists (SCRAs) reported to the National Programme on Substance Abuse Deaths (NPSAD) from England. Design: Case reports from NPSAD (England) where a SCRA was detected in post-mortem tissue(s) and/or implicated in the death were extracted, analyzed, and compared against non-SCRA-related deaths that occurred over the same time period (2012-2019). Findings: One hundred sixty-five death SCRA-related reports were extracted, with 18 different SCRAs detected. Following the first death in 2012, a subsequent sharp increase in reporting is evident. Acute SCRA use was the underlying cause of death in the majority of cases (75.8%) with cardiorespiratory complications the most frequently cited underlying physiological cause (13.4%). SCRA users were predominantly found dead (68.6%), with a large proportion of those witnessed becoming unresponsive described as suddenly collapsing (81.6%). Psychoactive polydrug use was detected in 90.3% of cases, with alcohol the most commonly co-detected (50.3%), followed by opioids (42.2%), benzodiazepines/Z-drugs (32.1%), stimulants (32.1%, [28.5% cocaine]), and cannabis (24.8%). Compared to all non-SCRA-related NPSAD deaths occurring over the same time period, SCRA-related decedents were more predominantly male (90.3% vs. 72.0%; p<0.01), and lived in more deprived areas (p<0.01). While a comparatively significant proportion of decedents were homeless (19.4% vs. 4.1%), living in a hostel (13.3% vs. 2.3%) or in prison (4.9% vs. 0.2%) at time of death (all p<0.01), the greatest majority of SCRA-related decedents were living in private residential accommodations (57.6%). Conclusions: This is the largest dataset regarding SCRA-related mortalities reported to date. Reporting of SCRA-related deaths in England have increased considerably, with polydrug use a specific concern. Lack of effective deterrents to SCRA use under current UK legislation, compounded by limited knowledge regarding the physiological impacts of SCRA consumption and their interaction with other co-administered substances are contributory factors to the occurrence of SCRA-related mortalities in an increasingly deprived demographic.

Entities:  

Keywords:  cannabinoid; drug-related death; novel psychoactive substance; spice; substance abuse; synthetic cannabinoid receptor agonist

Mesh:

Substances:

Year:  2021        PMID: 33998886      PMCID: PMC9418359          DOI: 10.1089/can.2020.0161

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  56 in total

1.  CYP3A4 Mediates Oxidative Metabolism of the Synthetic Cannabinoid AKB-48.

Authors:  Niels Bjerre Holm; Line Marie Nielsen; Kristian Linnet
Journal:  AAPS J       Date:  2015-05-23       Impact factor: 4.009

2.  Adding Spice to the Porridge: The development of a synthetic cannabinoid market in an English prison.

Authors:  Rob Ralphs; Lisa Williams; Rebecca Askew; Anna Norton
Journal:  Int J Drug Policy       Date:  2016-12-07

3.  Impact of legislation on NPS markets in Germany - The rise and fall of 5F-ADB.

Authors:  Sebastian Halter; Belal Haschimi; Lukas Mogler; Volker Auwärter
Journal:  Drug Test Anal       Date:  2020-03-13       Impact factor: 3.345

4.  Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants.

Authors:  Amy L Patton; Kathryn A Seely; Azure L Yarbrough; William Fantegrossi; Laura P James; Keith R McCain; Ryoichi Fujiwara; Paul L Prather; Jeffery H Moran; Anna Radominska-Pandya
Journal:  Biochem Biophys Res Commun       Date:  2018-03-10       Impact factor: 3.575

5.  In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA.

Authors:  Claudio Erratico; Noelia Negreira; Helia Norouzizadeh; Adrian Covaci; Hugo Neels; Kristof Maudens; Alexander L N van Nuijs
Journal:  Drug Test Anal       Date:  2015-04-12       Impact factor: 3.345

6.  Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.

Authors:  Jennifer Waugh; Javad Najafi; Leonard Hawkins; Simon L Hill; Michael Eddleston; J Allister Vale; John P Thompson; Simon H L Thomas
Journal:  Clin Toxicol (Phila)       Date:  2016-04-19       Impact factor: 4.467

Review 7.  Psychosocial interventions for cannabis use disorder.

Authors:  Peter J Gates; Pamela Sabioni; Jan Copeland; Bernard Le Foll; Linda Gowing
Journal:  Cochrane Database Syst Rev       Date:  2016-05-05

8.  Therapeutic Use of Synthetic Cannabinoids: Still an OpenIssue?

Authors:  Maria Antonietta De Luca; Liana Fattore
Journal:  Clin Ther       Date:  2018-09-01       Impact factor: 3.393

Review 9.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

10.  Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders.

Authors:  Eef L Theunissen; Nadia R P W Hutten; Natasha L Mason; Stefan W Toennes; Kim P C Kuypers; Johannes G Ramaekers
Journal:  Cannabis Cannabinoid Res       Date:  2019-03-13
View more
  2 in total

Review 1.  Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.

Authors:  Stefano D'Errico; Martina Zanon; Davide Radaelli; Monica Concato; Martina Padovano; Matteo Scopetti; Paola Frati; Vittorio Fineschi
Journal:  Biomedicines       Date:  2022-08-10

2.  Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.

Authors:  Adrian A Deen; Hugh Claridge; Richard D Treble; Hilary J Hamnett; Caroline S Copeland
Journal:  J Psychopharmacol       Date:  2021-06-29       Impact factor: 4.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.